secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-125920
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon reports Q3 net loss $22.4M; ACR-368 shows 62.5% ORR in endometrial cancer
--------------------------------------------------------------------------------

- Net loss Q3 2024: $22.4M vs $14.5M in Q3 2023; R&D expenses rose to $18.9M from $10.3M.
- Cash and securities $202.8M as of Sep 30, 2024; expected to fund into H2 2026.
- ACR-368 Phase 2b endometrial cancer: confirmed ORR 62.5% in OncoSignature-positive patients (p=0.009).
- ACR-2316 Phase 1 dose-escalation cohort fully enrolled; initial data expected H2 2025.
- Company sees endometrial cancer as first potential approval opportunity for ACR-368.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024125920/0000950170-24-125920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024125920/acrv-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer